Log in

ASX:OCCOrthocell Stock Price, Forecast & News

+0.02 (+5.48 %)
(As of 05/13/2020)
Today's Range
Now: A$0.39
50-Day Range
MA: A$0.35
52-Week Range
Now: A$0.39
Volume669,530 shs
Average VolumeN/A
Market Capitalization$71.11 million
P/E RatioN/A
Dividend YieldN/A
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.32 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 8 9360 2888



Sales & Book Value

Annual Sales$806,877.00
Cash FlowA$0.11 per share
Book ValueA$0.13 per share



Market Cap$71.11 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OCC News and Ratings via Email

Sign-up to receive the latest news and ratings for OCC and its competitors with MarketBeat's FREE daily newsletter.

Orthocell (ASX:OCC) Frequently Asked Questions

How has Orthocell's stock been impacted by COVID-19 (Coronavirus)?

Orthocell's stock was trading at A$0.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OCC stock has increased by 18.5% and is now trading at A$0.39. View which stocks have been most impacted by Coronavirus.

Has Orthocell been receiving favorable news coverage?

Media coverage about OCC stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Orthocell earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutOrthocell.

Who are some of Orthocell's key competitors?

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), VIRALYTICS Ltd/S (VRACY) and GP Strategies (GPX).

Who are Orthocell's key executives?

Orthocell's management team includes the following people:
  • Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 49)
  • Mr. Paul Anderson, CEO, MD & Exec. Director (Age 53)
  • Ms. Nicole Telford, Chief Financial Officer
  • Prof. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory Board
  • Monique Cannon, Regulatory Affairs & Compliance Mang.

What is Orthocell's stock symbol?

Orthocell trades on the ASX under the ticker symbol "OCC."

What is Orthocell's stock price today?

One share of OCC stock can currently be purchased for approximately A$0.39.

How big of a company is Orthocell?

Orthocell has a market capitalization of $71.11 million and generates $806,877.00 in revenue each year.

What is Orthocell's official website?

The official website for Orthocell is www.orthocell.com.au.

How can I contact Orthocell?

The company can be reached via phone at 61 8 9360 2888.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.